BHP vs BIOX

BHP's Piotroski F-Score of 6/9 indicates stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades significantly above its Graham Number of $27.35 and intrinsic value of $24.78, reflecting a substantial premium. Despite strong profitability metrics like 37.7% operating margin and 21.99% ROE, earnings and revenue growth are sharply negative year-over-year. Analysts consensus is a hold with a $57.00 target, below current price, suggesting limited upside.

The deterministic health scores paint a dire picture: BIOX has a Piotroski F-Score of just 2/9, indicating severe financial weakness. Despite low valuation multiples like a Price/Book of 0.29 and Price/Sales of 0.24, the company is unprofitable with a -17.72% profit margin and deteriorating fundamentals, including -16.40% YoY revenue growth and a -300% YoY EPS decline. Earnings volatility is extreme, with a history of massive negative surprises averaging -268.89% over the last four quarters, and the stock has lost over 85% of its value in five years. While the Forward P/E of 1.88 may appear attractive, it is unsupported by cash flow, balance sheet clarity, or consistent earnings, and the lack of an Altman Z-Score due to missing data further elevates risk.